Balancing Innovation and Safety: Navigating Global Medical Device Regulation

In the fast-paced world of medical technology, the drive for rapid innovation must be carefully balanced with patient safety. While pushing the boundaries of engineering is essential for advancing healthcare, it must never come at the expense of rigorous safety standards. When regulatory oversight fails to keep pace with technological advancement, or when loopholes allow for lower standards in certain markets, patient safety can be compromised.

Fortunately, the medical device industry is highly regulated. As technology evolves and global markets become more interconnected regulatory frameworks must adapt to ensure that all patients are afforded the same level of protection, regardless of where they live.

The Jurisdictional Loophole of “Export Only” Devices

The United States represents over 40% of global medical device revenue, and roughly 10% of Americans currently have a medical device implanted. While these devices generally improve quality of life, they are not without risks. Over the past decade, the FDA has received millions of adverse event reports, including tens of thousands of deaths associated with medical devices.

To maintain high domestic safety standards, the FDA requires extensive clinical validation of high risk products before a device can be marketed to US citizens. Despite this an ongoing regulatory gap exists: devices that lack FDA clearance or approval for domestic use can still receive an “Export Only” designation. As of 2018, approximately 4,600 medical devices were registered with the FDA as export-only.

This “Export Only” status allows manufacturers to sell these devices internationally. Foreign regulators sometimes approve these devices based on the FDA’s initial involvement, mistaking an FDA facility registration number for actual product clearance.

How does this happen? The primary driver is differential device classification. A device deemed high-risk by the FDA might be classified as lower-risk by an importing country’s regulatory body. For example, while implantable devices containing biologics require stringent clinical validation globally, standard implantable devices (such as IIa devices intended for diagnostic or monitoring purposes) may only require a CE mark in Europe or Australia. This lower classification allows a device that failed US clinical scrutiny to enter foreign markets with a significantly reduced burden of evidence. Patients in these importing countries are rarely informed of the device’s domestic regulatory status.

Update: Joint replacements have been Class III in the EU since Directive 2005/50/EC took effect in September 2007, and in Australia since July 2012. The MDR maintains this under Rule 8.

Regulatory Standards Must Evolve with Technology

Beyond international trade loopholes, local regulators face a more fundamental challenge: keeping pace with the complexity of modern medical devices.

It is no longer enough to rely on static safety standards. Regulators must continuously reassess their frameworks to ensure they are adequate for evaluating novel technologies. As devices become more complex, advanced statistical and computational methods (such as causal inference, agent-based models, and Bayesian methods) are becoming essential tools for calibrating risk and validating device safety.

When a device combines hardware with software, particularly artificial intelligence (AI), the need for dynamic regulation increases exponentially. Regulators must now evaluate the reliability of machine learning algorithms, track software degradation over time, assess cybersecurity vulnerabilities, and monitor how AI adapts to real-world stimuli; all alongside the physical safety of the device itself.

Lessons from Recent Medical Device Litigation

Recent class-action lawsuits highlight the consequences of inadequate validation and testing across the industry.

Johnson & Johnson: J&J has faced significant litigation regarding its vaginal mesh products and electrosurgical devices. In the mesh cases, thousands of adverse events were reported to the FDA, including serious injuries and a loss of quality of life for patients. Similarly, lawsuits regarding surgical tools alleged that the devices caused burn injuries to patients. These cases underscore the critical need for comprehensive pre-market testing, both in clinical trials and post-market surveillance, to ensure long-term safety.

Pulse Oximeters and Racial Bias: Recent legal action against Apple regarding its blood oxygen sensor highlighted a systemic issue in pulse oximetry technology. This has posed a problem for certain users who may rely on the data for health status. Darker skin has been found to absorb more light at certain wavelengths, these sensors can provide falsely elevated blood oxygen readings for people with darker skin tones. This limitation, which spans across multiple manufacturers, potentially contributed to adverse health outcomes during the pandemic. The Apple Watch feature was marketed as a wellness tool rather than an FDA-cleared medical device, it thereby bypassed the clinical validation required for medical-grade pulse oximeters. This issue could have been better mitigated if it was subject to a clinical investigation and that study had recruited a broad spectrum of participants, stratified by skin tone, and if those limitations had been transparently reported on product labeling.

Strengthening Global Regulatory Oversight

To maintain trust in medical technology, regulatory bodies worldwide must take proactive steps to close existing loopholes and prepare for future complexities.

1. Flagging “Export Only” Devices: Any device given “Export Only” status by the FDA, or its equivalent by another regulatory body, should be automatically flagged by importing national regulators as requiring additional scrutiny. Local agencies should demand the specific clinical data that led to the device failing domestic approval in its country of origin.
2. Harmonising Risk Classifications: Global regulatory bodies must work toward harmonising device classifications. An implantable device deemed high-risk in one developed nation should not bypass clinical scrutiny simply by crossing a border.
3. Dynamic Post-Market Surveillance: As AI and software-driven devices become the norm, regulators must require continuous post-market surveillance. Real-world data collection must be standard practice to ensure algorithms do not drift or develop biases over time.

Putting Patients First

The ultimate goal of medical device development is to improve health outcomes, alleviate suffering, and save lives. A culture of responsible innovation requires developers to prioritize patient safety over short-term financial gains.

While collecting international data on “Export Only” devices can be an attractive way for companies to generate revenue and gather real-world evidence for future FDA applications, it cannot be done at the expense of uninformed patients. National regulatory agencies must maintain strict classification and clinical evidence standards to ensure their citizens are not exposed to undue, undisclosed risks.

Collaboration and Transparency

The medical device industry must embrace a culture of transparency. Open dialogue among developers, regulators, healthcare professionals, and patients ensures a holistic approach to device development. Sharing data regarding device failures, adverse events, and software vulnerabilities can help prevent the repetition of past mistakes across the industry.

By prioritising patient well-being, adopting transparent practices, and modernising regulatory frameworks to match the pace of innovation, the medical technology sector can continue to advance safely and ethically.

---

---

Further Reading & Sources

• Drugs and Devices: Comparison of European and U.S. Approval Processes – ScienceDirect
• Addressing the Medical Device Safety Crisis – The Regulatory Review
• Medtech Regulation: FDA and EU MDR Outlook – MedTech Dive
• Global Medical Devices Market Forecast – Market Data Forecast
• FDA Permits ‘Export Only’ Medical Devices – Industrial Equipment News
• FDA Issues ‘Most Serious’ Recall Over Johnson & Johnson Surgical Tools
• Jury Award in Vaginal Mesh Lawsuit Could Open Flood Gates – MDDI Online
• Lawsuit Alleges Apple Watch’s Blood Oxygen Sensor ‘Racially Biased’ – ABC News / Inferse